{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:31:26Z","timestamp":1769315486961,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z191100006619012"],"award-info":[{"award-number":["Z191100006619012"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.semarthrit.2022.152011","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:19:43Z","timestamp":1650539983000},"page":"152011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Serum levels of anti-transcriptional intermediary factor 1-\u03b3 autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis"],"prefix":"10.1016","volume":"55","author":[{"given":"Lining","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152011_bib0001","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0004","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/BOR.0000000000000641","article-title":"The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome","volume":"31","author":"Lu","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis\u2013A clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"American Academy of Neurology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0006","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0007","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: a comprehensive review","volume":"52","author":"Tiniakou","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0009","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/sj.onc.1202655","article-title":"TIF1\u03b3, a novel member of the transcriptional intermediary factor 1 family","volume":"18","author":"Venturini","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0011","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","volume":"55","author":"Aggarwal","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0012","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/rheumatology\/key310","article-title":"Changes in antibody titres in patients with anti-transcription intermediary factor 1-gamma antibody-positive idiopathic inflammatory myositis","volume":"58","author":"Abe","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152011_bib0013","first-page":"67","article-title":"Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis:a longitudinal study","volume":"38","author":"Dani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0014","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/ced.13180","article-title":"Expression of the autoantigen TRIM33\/TIF1gamma in skin and muscle of patients with dermatomyositis is upregulated, together with markers of cellular stress","volume":"42","author":"Scholtissek","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1756-185X.13424","article-title":"Anti-TIF1gamma antibody and the expression of TIF1gamma in idiopathic inflammatory myopathies","volume":"22","author":"Kim","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0016","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nature09542","article-title":"TRIM24 links a non-canonical histone signature to breast cancer","volume":"468","author":"Tsai","year":"2010","journal-title":"NatureNature"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0017","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1245\/s10434-009-0795-8","article-title":"KAP1 is associated with peritoneal carcinomatosis in gastric cancer","volume":"17","author":"Yokoe","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0018","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.ajpath.2010.12.026","article-title":"Prognostic significance of TRIM24\/TIF-1alpha gene expression in breast cancer","volume":"178","author":"Chambon","year":"2011","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152011_bib0019","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0020","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/art.23963","article-title":"Reliability and validity of the myositis disease activity assessment tool","volume":"58","author":"Sultan","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"10.1016\/j.semarthrit.2022.152011_bib0021","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2022.152011_bib0022","doi-asserted-by":"crossref","first-page":"i82","DOI":"10.1136\/annrheumdis-2011-200587","article-title":"New approaches to the assessment and treatment of the idiopathic inflammatory myopathies","volume":"71","author":"Miller","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0024","first-page":"365","article-title":"The expression of major histocompatibility complex in idiopathic inflammatory myopathies and its cIinical application","volume":"12","author":"Lu","year":"2008","journal-title":"Chin J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0025","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.23012","article-title":"International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials","volume":"57","author":"Wedderburn","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0026","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2013-203396","article-title":"Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease","volume":"74","author":"Varsani","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0027","first-page":"76","article-title":"The role of muscle biopsy score in assessing disease activity in adult patients with idiopathic inflammatory myopathies","volume":"23","author":"Zhang","year":"2019","journal-title":"Chin J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0028","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0029","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0030","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/jnnp-2016-313418","article-title":"Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis","volume":"87","author":"Dalakas","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0031","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0033","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/25785826.2020.1791402","article-title":"Transcriptional intermediary factor 1 (TIF1) and anti-TIF1gamma antibody-positive dermatomyositis","volume":"44","author":"Kotobuki","year":"2021","journal-title":"Immunol Med"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0036","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1346-8138.15284","article-title":"Clinical significance of serum levels of anti-transcriptional intermediary factor 1-gamma antibody in patients with dermatomyositis","volume":"47","author":"Ikeda","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0037","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2022.152011_bib0038","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.38863","article-title":"Expression of the dermatomyositis autoantigen transcription intermediary factor 1gamma in regenerating muscle","volume":"67","author":"Mohassel","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:02Z","timestamp":1758733742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":38,"alternative-id":["S0049017222000622"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152011","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum levels of anti-transcriptional intermediary factor 1-\u03b3 autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152011"}}